Mary O'Brien

Mary O'Brien


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2022 in The Lancet Oncology
Verified
Journal Article
Closed access
MOMary O'Brien
Mary O'Brien
LPLuis Paz-Ares
Luis Paz-Ares
SMSandrine Marreaud
Sandrine Marreaud
UDUrania Dafni
Urania Dafni
KOKersti Oselin
Kersti Oselin
SPSolange Peters
Solange Peters

1 June 2020 in European Journal of Cancer
Verified
Journal Article
Closed access
SPSimon Page
Simon Page
CMCharlotte Milner-Watts
Charlotte Milner-Watts
MPMarco Perna
Marco Perna
UJUrska Janzic
Urska Janzic
NVNatalia Vidal
Natalia Vidal
MOMary O'Brien
Mary O'Brien

1 April 2019 in Therapies
Verified
Journal Article
Closed access
LSLucie-Marie Scailteux
Lucie-Marie Scailteux
CDCatherine Droitcourt
Catherine Droitcourt
FBFrédéric Balusson
Frédéric Balusson
ENEmmanuel Nowak
Emmanuel Nowak
SKSandrine Kerbrat
Sandrine Kerbrat
EOEmmanuel Oger
Emmanuel Oger

26 January 2010 in British Journal of Cancer
Verified
Journal Article
Open access
MPM Puglisi
M Puglisi
SDS Dolly
S Dolly
AFA Faria
A Faria
JMJ S Myerson
J S Myerson
SPS Popat
S Popat
MOMary O'Brien
Mary O'Brien
Small cell lung cancer (SCLC) is a significant health problem worldwide because of its high propensity for relapse. This review discusses existing and future therapies for the treatment of SCLC.

1 May 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
LSLucie-Marie Scailteux
Lucie-Marie Scailteux
SVSébastien Vincendeau
Sébastien Vincendeau
FBFrédéric Balusson
Frédéric Balusson
CLChristophe Leclercq
Christophe Leclercq
AHAndré Happe
André Happe
EOEmmanuel Oger
Emmanuel Oger

16 December 2014 in BMC Palliative Care
Verified
Journal Article
Open access
PDF file
Haris CharalambousHaris Charalambous
Haris Charalambous
APAthanasios Pallis
Athanasios Pallis
BHBaktiar Hasan
Baktiar Hasan
MOMary O'Brien
Mary O'Brien
To examine availability of Palliative Care (PC) services and referral patterns of European Lung cancer specialists to PC. All members of the EORTC Lung Cancer Group (LCG) were asked via email to participate in an on-line survey. 50 out of 170 (29.4%) replied: 24 medical oncologists, 14 radiation/clinical oncologists, 11 pulmonologists and 1 thoracic surgeon. All but two of respondents (96%) had access to at least one component of PC services. In terms of referral of patients to PC almost 75% of respondents would refer most of their patients when there were no treatment options or at the end of life, while only 22% would refer patients at earlier stages of disease. Barriers for referral to PC were negative attitudes of patients to PC (26%), lack of availability of PC services (20%), lack of expertise of PC physicians(18%), the belief that referral to PC signifies abandoning patients (8%), and that PC specialists discourage active oncological therapy (8%). Whilst most of the respondents expressed positive attitudes, 12-22% had overtly negative attitudes towards PC. Seventy-eight (78%) of respondents expressed an interest to participate in a trial of early PC (EPC). Despite good availability of SPC services at institutions of members of the EORTC LCG, and most respondents expressing positive attitudes towards PC, their practice involved referral of patients to PC late in the disease trajectory, hence Lung Cancer specialists in Europe have not adopted the practice of EPC concurrent with active oncological care.